Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 759.76 Million CNY | -87.59% |
| 2022 | 3.34 Billion CNY | 20.54% |
| 2021 | 2.77 Billion CNY | 52.83% |
| 2020 | 1.81 Billion CNY | 275.36% |
| 2019 | 484.03 Million CNY | 55.16% |
| 2018 | 311.95 Million CNY | 18.82% |
| 2017 | 262.54 Million CNY | 38.93% |
| 2016 | 188.97 Million CNY | 16.1% |
| 2015 | 162.77 Million CNY | 304.25% |
| 2014 | 40.26 Million CNY | -44.12% |
| 2013 | 72.06 Million CNY | 26.5% |
| 2012 | 56.96 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 116.7 Million CNY | 408.02% |
| 2024 Q1 | -37.88 Million CNY | -150.99% |
| 2024 Q3 | 960.19 Thousand CNY | -99.18% |
| 2023 Q3 | 306.11 Million CNY | 78.11% |
| 2023 Q4 | 74.29 Million CNY | -75.73% |
| 2023 FY | 415.32 Million CNY | -87.59% |
| 2023 Q1 | 164.44 Million CNY | -52.77% |
| 2023 Q2 | 171.86 Million CNY | 4.51% |
| 2022 Q3 | 945.98 Million CNY | -3.27% |
| 2022 Q2 | 977.95 Million CNY | -9.04% |
| 2022 Q1 | 1.07 Billion CNY | 46.47% |
| 2022 FY | 3.34 Billion CNY | 20.54% |
| 2022 Q4 | 348.16 Million CNY | -63.2% |
| 2021 Q2 | 619.43 Million CNY | -5.57% |
| 2021 FY | 2.77 Billion CNY | 52.83% |
| 2021 Q4 | 734.02 Million CNY | -4.34% |
| 2021 Q1 | 655.95 Million CNY | 19.57% |
| 2021 Q3 | 767.34 Million CNY | 23.88% |
| 2020 Q1 | 71.04 Million CNY | -20.48% |
| 2020 Q2 | 606.43 Million CNY | 753.65% |
| 2020 FY | 1.81 Billion CNY | 275.36% |
| 2020 Q4 | 548.6 Million CNY | -7.14% |
| 2020 Q3 | 590.78 Million CNY | -2.58% |
| 2019 Q1 | 58.07 Million CNY | -29.92% |
| 2019 FY | 484.03 Million CNY | 55.16% |
| 2019 Q4 | 89.33 Million CNY | -48.97% |
| 2019 Q3 | 175.07 Million CNY | 8.37% |
| 2019 Q2 | 161.55 Million CNY | 178.19% |
| 2018 Q4 | 82.87 Million CNY | -12.7% |
| 2018 FY | 311.95 Million CNY | 18.82% |
| 2018 Q3 | 94.92 Million CNY | -18.14% |
| 2018 Q2 | 115.95 Million CNY | 536.76% |
| 2018 Q1 | 18.2 Million CNY | -74.37% |
| 2017 Q1 | 17.11 Million CNY | -65.29% |
| 2017 Q3 | 73.78 Million CNY | -26.66% |
| 2017 Q4 | 71.04 Million CNY | -3.72% |
| 2017 Q2 | 100.6 Million CNY | 487.98% |
| 2017 FY | 262.54 Million CNY | 38.93% |
| 2016 Q4 | 49.29 Million CNY | -23.8% |
| 2016 Q3 | 64.69 Million CNY | 0.0% |
| 2016 FY | 188.97 Million CNY | 16.1% |
| 2015 Q4 | 25.56 Million CNY | 0.0% |
| 2015 FY | 162.77 Million CNY | 304.25% |
| 2014 FY | 40.26 Million CNY | -44.12% |
| 2013 FY | 72.06 Million CNY | 26.5% |
| 2012 FY | 56.96 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 646.8 Million CNY | -17.464% |
| Joinn Laboratories(China)Co.,Ltd. | 507.09 Million CNY | -49.826% |
| WuXi AppTec Co., Ltd. | 11.87 Billion CNY | 93.601% |
| Autobio Diagnostics Co., Ltd. | 1.36 Billion CNY | 44.37% |
| Thalys Medical Technology Group Inc. | -180.32 Million CNY | 521.336% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | -356.901% |